My point is that Abbvie will soon know the value of what *could* become ENTA's greatest asset; ABT-493. Readouts are happening as we speak.
It occurs to me that the commercial value that you refer to, Abbvie also has a VERY good idea, since they probably at this point know exactly where they will price the 3-D program.
They will do it in a manner which should best commercialize the 3D program.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.